Nautilus Biotechnology | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.12, beating the estimate of USD -0.145.

EBIT: As of FY2026 Q1, the actual value is USD -17.57 M.

First Quarter 2026 Financial Results

Operating Expenses

Total operating expenses for Nautilus Biotechnology, Inc. were $16.1 million for the first quarter of 2026, representing a 14% or $2.7 million decrease compared to $18.8 million in the corresponding prior year period, primarily due to lower salaries, benefits, stock-based compensation, and facilities costs . Research and development expenses were $9.7 million in Q1 2026, down from $11.5 million in Q1 2025 . Selling, general and administrative expenses were $6.4 million in Q1 2026, a decrease from $7.3 million in Q1 2025 .

Net Loss

Nautilus Biotechnology, Inc. reported a net loss of - $14.7 million for the first quarter of 2026, an improvement from a net loss of - $16.6 million in the corresponding prior year period .

Cash, Cash Equivalents, and Investments

As of March 31, 2026, cash, cash equivalents, and investments totaled $143.4 million .

Balance Sheet Highlights

As of March 31, 2026, total assets were $177.8 million, down from $191.1 million as of December 31, 2025 . Total liabilities were $33.4 million, a decrease from $34.1 million as of December 31, 2025 . Total stockholders’ equity stood at $144.4 million as of March 31, 2026, compared to $157.0 million as of December 31, 2025 .

Cash Flow Highlights

Net cash used in operating activities was - $13.1 million in Q1 2026, compared to - $13.9 million in Q1 2025 . Net cash provided by investing activities was $14.2 million in Q1 2026, down from $19.5 million in Q1 2025 . Net cash provided by financing activities was $1.1 million in Q1 2026, significantly higher than $0.02 million in Q1 2025 . The net increase in cash, cash equivalents and restricted cash was $2.2 million in Q1 2026, compared to $5.6 million in Q1 2025 . Cash, cash equivalents and restricted cash at the end of the period totaled $15.6 million in Q1 2026, down from $34.2 million in Q1 2025 .

Business Highlights and Operational Metrics

Nautilus Biotechnology, Inc. initiated its Iterative Mapping Early Access Program, with Baylor College of Medicine becoming the first customer for a National Institutes of Health-funded cancer study . The company also advanced the processing and analysis of Tau proteoform samples from collaborators to support platform validation and future scientific publications . Amber Faust was appointed as Vice President of Global Sales to lead Early Access customer expansion and drive Voyager™ Platform adoption . Furthermore, Nautilus Biotechnology advanced the development of a next-generation assay format designed to improve probe compatibility, performance, and scalability .

Outlook

Nautilus Biotechnology, Inc. made measurable progress toward commercialization in Q1, with early customer engagement reinforcing the platform’s value . The company expects efforts to advance broadscale capabilities and add experienced sales leadership to position it to scale Early Access and progress toward full commercial availability . Nautilus Biotechnology anticipates its business operations and financial performance to continue, with expectations regarding operating expenses, cash runway, and the timing of the Nautilus Voyager™ platform launch and full commercial availability .